Sensus Healthcare Inc Stock Price, News & Analysis

Sensus Healthcare (Nasdaq: SRTS) announced the passing of longtime director William “Bill” McCall on October 31, 2025. McCall supported Sensus since 2009, led the Company’s initial capital raise in 2010, and joined the board in 2015, providing counsel and leadership throughout his tenure.

Management praised his financial acumen, 50+ year advisory career, charitable work in Tennessee, and said the Board will honor his memory and communicate any governance changes in due course.

Sensus Healthcare (Nasdaq: SRTS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a business update conference call beginning at 4:30 p.m. Eastern to review results and answer questions.

Participants are encouraged to pre-register to receive a unique dial-in to bypass the operator; pre-registration is available up to and after the call start time. Live access is also available by dialing 844-481-2811 (U.S./Canada) or 412-317-0676 (International). The call will be webcast live and archived in the Investor Relations section at www.sensushealthcare.com.

A telephone replay will be available through December 6, 2025 by dialing U.S. toll free 877-344-7529, Canada toll free 855-669-9658, or International 412-317-0088 and entering replay code 5165150.

Sensus Healthcare (NASDAQ: SRTS) announced positive results from a study published in Dermatologic Therapy demonstrating the effectiveness of combining their superficial radiotherapy (SRT) technology with punch excision for treating keloids. The study, conducted at the Hospital for Skin Diseases in Nanjing, China, evaluated 60 patients and showed statistically significant improvements in pain, itching, thickness, and irregularity of keloid scars after one year.

The research highlights that keloids, affecting 4% to 16% of the population, particularly impact individuals with higher melanin levels. The combination therapy showed no severe adverse reactions, supporting SRT's safety profile and its potential as a treatment option for this serious medical condition that disproportionately affects African, Hispanic, and Asian populations.

Sensus Healthcare (NASDAQ:SRTS) reported Q2 2025 financial results, with revenues of $7.3 million, down from $9.2 million in Q2 2024. The company shipped 19 SRT systems, including four to China, while experiencing a 27% increase in FDA treatment volume over Q1. The quarter resulted in a net loss of $1.0 million ($0.06 per share).

Key developments include signing five new Fair Deal Agreements, receiving MDSAP certification for their SRT product portfolio, and partnering with Radiology Oncology Systems (ROS) for distribution. The company maintained a strong financial position with $22.2 million in cash and no debt. A proposed Medicare Physician Fee Schedule change could positively impact SRT technology adoption starting January 2026.

Sensus Healthcare (NASDAQ: SRTS), a medical device company focused on non-invasive treatments for skin conditions, has scheduled its Q2 2025 earnings release for August 7, 2025. The company will host a conference call at 4:30 PM Eastern time to discuss financial results and provide a business update.

Participants can pre-register for the call using a dedicated link to receive a unique dial-in number. Alternative dial-in options include 844-481-2811 (U.S./Canada) and 412-317-0676 (International). A webcast will be available live and archived in the Investor Relations section of the company's website. A telephone replay will be accessible until September 7th using replay code 8187211.

Sensus Healthcare (NASDAQ: SRTS) has achieved Medical Device Single Audit Program (MDSAP) certification for its complete portfolio of superficial radiation therapy (SRT) systems, including the SRT-100®, SRT-100+™, and SRT-100 Vision™.

The MDSAP certification streamlines regulatory compliance by allowing a single audit to satisfy requirements across multiple jurisdictions including the FDA, Health Canada, Brazil's ANVISA, Japan's PMDA, and Australia's TGA. This certification is expected to accelerate the company's international expansion by simplifying regulatory processes and reducing approval timelines in key global markets.

Upon receiving FDA clearance, Sensus Healthcare's TransDermal Infusion (TDI) product is also anticipated to receive MDSAP certification, further enhancing its international commercial potential.

Sensus Healthcare (NASDAQ:SRTS) has announced a strategic partnership with Radiology Oncology Systems (ROS) as its primary U.S. distribution partner for superficial radiotherapy (SRT) systems. ROS will sell Sensus's SRT-100™ and SRT-100 Vision™ systems to hospital-based radiation oncology departments and freestanding oncology centers nationwide.

The partnership leverages ROS's 30-year experience and presence across all 50 states to accelerate adoption of Sensus's non-invasive radiotherapy technologies. Initial orders are expected by Q4 2025, with potential expansion to international markets. This collaboration represents Sensus's strategic move to expand beyond dermatology into hospital and multidisciplinary oncology environments.

Sensus Healthcare (NASDAQ: SRTS) reported Q1 2025 financial results with revenues of $8.3 million, down from $10.7 million in Q1 2024. The company shipped 21 SRT systems during the quarter, including 15 to a large customer. Despite posting a net loss of $2.6 million ($0.16 per share), management remains optimistic, forecasting profitability for the next three quarters and full year. The company reported a 65% increase in treatment volume from FDA-based systems over the previous quarter. Key investments were made in sales, marketing, and R&D, including product development and lobbying efforts. Cash position stood at $19.1 million as of March 31, 2025. Management expects FDA revenue to contribute significantly in H2 2025 and aims to sign 3-5 additional multisite FDA customers this year.

Sensus Healthcare (NASDAQ: SRTS) is promoting Skin Cancer Awareness Month in May 2025 through educational initiatives and highlighting its non-invasive skin cancer treatment technologies. The company's flagship products, IG-SRT and SRT-100 Vision, provide non-invasive treatment options for non-melanoma skin cancers, delivering precise radiation therapy while preserving healthy tissue. Sensus offers its technologies through the Fair Deal Agreement, a shared-revenue program launched a year ago that requires no upfront capital from dermatology practices. The company is conducting awareness campaigns through newsletters, social media, and healthcare professional collaborations, while also providing educational resources about skin cancer prevention, including tips on sun protection, regular screenings, and avoiding UV exposure.